These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 34714587)

  • 1. A comprehensive review on glucokinase activators: Promising agents for the treatment of Type 2 diabetes.
    Thilagavathi R; Hosseini-Zare MS; Malini M; Selvam C
    Chem Biol Drug Des; 2022 Feb; 99(2):247-263. PubMed ID: 34714587
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of orally active hepatoselective glucokinase activators for treatment of Type II Diabetes Mellitus.
    Xu J; Lin S; Myers RW; Trujillo ME; Pachanski MJ; Malkani S; Chen HS; Chen Z; Campbell B; Eiermann GJ; Elowe N; Farrer BT; Feng W; Fu Q; Kats-Kagan R; Kavana M; McMasters DR; Mitra K; Tong X; Xu L; Zhang F; Zhang R; Addona GH; Berger JP; Zhang B; Parmee ER
    Bioorg Med Chem Lett; 2017 May; 27(9):2063-2068. PubMed ID: 28284809
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel, highly potent systemic glucokinase activators for the treatment of Type 2 Diabetes Mellitus.
    Xu J; Lin S; Myers RW; Addona G; Berger JP; Campbell B; Chen HS; Chen Z; Eiermann GJ; Elowe NH; Farrer BT; Feng W; Fu Q; Kats-Kagan R; Kavana M; Malkani S; McMasters DR; Mitra K; Pachanski MJ; Tong X; Trujillo ME; Xu L; Zhang B; Zhang F; Zhang R; Parmee ER
    Bioorg Med Chem Lett; 2017 May; 27(9):2069-2073. PubMed ID: 28284804
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recent updates on glucokinase activators for the treatment of type 2 diabetes mellitus.
    Grewal AS; Sekhon BS; Lather V
    Mini Rev Med Chem; 2014; 14(7):585-602. PubMed ID: 25052034
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recent advances in glucokinase activators for the treatment of type 2 diabetes.
    Pal M
    Drug Discov Today; 2009 Aug; 14(15-16):784-92. PubMed ID: 19520181
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of a potent glucokinase activator with a favorable liver and pancreas distribution pattern for the treatment of type 2 diabetes mellitus.
    Fujieda H; Kogami M; Sakairi M; Kato N; Makino M; Takahashi N; Miyazawa T; Harada S; Yamashita T
    Eur J Med Chem; 2018 Aug; 156():269-294. PubMed ID: 30006171
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical investigation of glucokinase activators for the restoration of glucose homeostasis in diabetes.
    Li P; Zhu D
    J Diabetes; 2024 May; 16(5):e13544. PubMed ID: 38664885
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent clinical advances of glucokinase activators in the treatment of diabetes mellitus type 2.
    Li W; Zhang X; Sun Y; Liu Z
    Pharmazie; 2020 Jun; 75(6):230-235. PubMed ID: 32539915
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recent Developments in Medicinal Chemistry of Allosteric Activators of Human Glucokinase for Type 2 Diabetes Mellitus Therapeutics.
    Grewal AS; Lather V; Charaya N; Sharma N; Singh S; Kairys V
    Curr Pharm Des; 2020; 26(21):2510-2552. PubMed ID: 32286938
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Research and development of glucokinase activators for diabetes therapy: theoretical and practical aspects.
    Matschinsky FM; Zelent B; Doliba NM; Kaestner KH; Vanderkooi JM; Grimsby J; Berthel SJ; Sarabu R
    Handb Exp Pharmacol; 2011; (203):357-401. PubMed ID: 21484579
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Small molecule glucokinase activators as glucose lowering agents: a new paradigm for diabetes therapy.
    Guertin KR; Grimsby J
    Curr Med Chem; 2006; 13(15):1839-43. PubMed ID: 16787225
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel glucokinase activators: a patent review (2008 - 2010).
    Sarabu R; Berthel SJ; Kester RF; Tilley JW
    Expert Opin Ther Pat; 2011 Jan; 21(1):13-33. PubMed ID: 21155690
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Insights to the emerging potential of glucokinase activators as antidiabetic agent.
    Mehra A; Kumar S; Mittal A; Kohli R; Mittal A
    Pharm Pat Anal; 2024; 13(1-3):53-71. PubMed ID: 39316577
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recent Updates on Glucokinase Activators and Glucokinase Regulatory Protein Disrupters for the Treatment of Type 2 Diabetes Mellitus.
    Kaushik A; Kaushik M
    Curr Diabetes Rev; 2019; 15(3):205-212. PubMed ID: 30039763
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A patent review of glucokinase activators and disruptors of the glucokinase--glucokinase regulatory protein interaction: 2011-2014.
    Filipski KJ; Pfefferkorn JA
    Expert Opin Ther Pat; 2014 Aug; 24(8):875-91. PubMed ID: 24821087
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TTP399: an investigational liver-selective glucokinase (GK) activator as a potential treatment for type 2 diabetes.
    Egan A; Vella A
    Expert Opin Investig Drugs; 2019 Sep; 28(9):741-747. PubMed ID: 31398075
    [No Abstract]   [Full Text] [Related]  

  • 17. Discovery of (S)-6-(3-cyclopentyl-2-(4-(trifluoromethyl)-1H-imidazol-1-yl)propanamido)nicotinic acid as a hepatoselective glucokinase activator clinical candidate for treating type 2 diabetes mellitus.
    Pfefferkorn JA; Guzman-Perez A; Litchfield J; Aiello R; Treadway JL; Pettersen J; Minich ML; Filipski KJ; Jones CS; Tu M; Aspnes G; Risley H; Bian J; Stevens BD; Bourassa P; D'Aquila T; Baker L; Barucci N; Robertson AS; Bourbonais F; Derksen DR; Macdougall M; Cabrera O; Chen J; Lapworth AL; Landro JA; Zavadoski WJ; Atkinson K; Haddish-Berhane N; Tan B; Yao L; Kosa RE; Varma MV; Feng B; Duignan DB; El-Kattan A; Murdande S; Liu S; Ammirati M; Knafels J; Dasilva-Jardine P; Sweet L; Liras S; Rolph TP
    J Med Chem; 2012 Feb; 55(3):1318-33. PubMed ID: 22196621
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent drug development of dorzagliatin, a new glucokinase activator, with the potential to treat Type 2 diabetes: A review study.
    Jiang Y; Wang L; Dong Z; Xia B; Pang S
    J Diabetes; 2024 Jun; 16(6):e13563. PubMed ID: 38783768
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery, structure-activity relationships, pharmacokinetics, and efficacy of glucokinase activator (2R)-3-cyclopentyl-2-(4-methanesulfonylphenyl)-N-thiazol-2-yl-propionamide (RO0281675).
    Haynes NE; Corbett WL; Bizzarro FT; Guertin KR; Hilliard DW; Holland GW; Kester RF; Mahaney PE; Qi L; Spence CL; Tengi J; Dvorozniak MT; Railkar A; Matschinsky FM; Grippo JF; Grimsby J; Sarabu R
    J Med Chem; 2010 May; 53(9):3618-25. PubMed ID: 20405948
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Medicinal chemistry approaches for glucokinase activation to treat type 2 diabetes.
    Pal M
    Curr Med Chem; 2009; 16(29):3858-74. PubMed ID: 19747136
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.